Adam Simpson, Icosavax CEO
May 23, 2023 07:16 AM EDTUpdated 08:55 AM
Financing
R&D

Icosavax push­es for­ward com­bo RSV-hM­PV vac­cine and an­nounces di­rect stock of­fer­ing

Katherine Lewin

News Reporter

Seat­tle-based Icosavax may have failed in its at­tempt at a Covid-19 vac­cine in 2022, but it re­leased ear­ly da­ta on its bi­va­lent vac­cine can­di­date for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times